Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 26: - The gentleman who was sober and could not focus
Published online by Cambridge University Press: 03 April 2024
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
Which of the following apply to borderline intellectual functioning (BIF)?
Keywords
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 441 - 452Publisher: Cambridge University PressPrint publication year: 2024
References
Cortese, S, Adamo, N, Del Giovane, C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5:727–38Google ScholarPubMed
Faraone, SV, Banaschewski, T, Coghill, D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev 2021; 128:789–818CrossRefGoogle ScholarPubMed
Faraone, SV, Radonjić, NV. Neurobiology of Attention-Deficit/Hyperactivity Disorder. In Tasman, A, et al., eds., Tasman’s Psychiatry. Cham: Springer, 2023Google Scholar
Fernell, E, Gillberg, C. Borderline intellectual functioning. Handb Clin Neurol 2020; 174:77–81CrossRefGoogle ScholarPubMed
Katwala, J, Kumar, AK, Sejpal, JJ, et al. Therapeutic rationale for low dose doxepin in insomnia patients. Asian Pac J Trop Dis 2013; 3:331–6CrossRefGoogle Scholar
Khoury, NM, Radonjić, NV, Albert, AB, et al. From structural disparities to neuropharmacology: a review of adult attention-deficit/hyperactivity disorder medication treatment. Child Adolesc Psychiatr Clin N Am 2022; 31:343–61CrossRefGoogle ScholarPubMed
Mariani, JJ, Levin, FR. Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict 2007; 16 Suppl 1:45–54; quiz 55–6CrossRefGoogle ScholarPubMed
Rose, E, Bramham, J, Young, S, et al. Neuropsychological characteristics of adults with comorbid ADHD and borderline/mild intellectual disability. Res Dev Disabil 2009; 30:496–502CrossRefGoogle ScholarPubMed
Stahl, SM. Attention Deficit Hyperactivity Disorder and Its Treatment, 5th edn. Cambridge: Cambridge University Press, 2021.CrossRefGoogle Scholar